{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=40",
    "query": {
      "condition": "Genetic Change",
      "page": 40
    },
    "page_size": 10
  },
  "pagination": {
    "page": 40,
    "page_size": 10,
    "total_count": 1795,
    "total_pages": 180,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=41&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=39&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T07:05:56.571Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00010101",
      "title": "Genetic Study of Brain Tumors in Young Children",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Central Nervous System Tumor, Pediatric"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Pediatric Brain Tumor Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "3 Years",
        "sex": "ALL",
        "summary": "Up to 3 Years"
      },
      "enrollment_count": 38,
      "start_date": "2001-03",
      "completion_date": "2004-08",
      "has_results": false,
      "last_update_posted_date": "2011-07-20",
      "last_synced_at": "2026-11-15T07:05:56.571Z",
      "location_count": 4,
      "location_summary": "Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00010101"
    },
    {
      "nct_id": "NCT03944265",
      "title": "Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Activating ALK Gene Mutation Negative",
        "Activating EGFR Gene Mutation Negative",
        "Activating ROS1 Gene Mutation Negative",
        "Health Care Provider",
        "Lung Non-Small Cell Carcinoma",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Counseling",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Medical Chart Review",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2019-02-08",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-11-15T07:05:56.571Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03944265"
    },
    {
      "nct_id": "NCT03256968",
      "title": "PTC Study to Evaluate Ataluren in Combination With Ivacaftor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Ataluren",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2017-01-27",
      "completion_date": "2018-12-31",
      "has_results": true,
      "last_update_posted_date": "2020-03-26",
      "last_synced_at": "2026-11-15T07:05:56.571Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03256968"
    },
    {
      "nct_id": "NCT07703462",
      "title": "Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis (ALS)"
      ],
      "interventions": [
        {
          "name": "nL-TARDB-002",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "n-Lorem Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1,
      "start_date": "2026-12",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-11-15T07:05:56.571Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07703462"
    },
    {
      "nct_id": "NCT03602079",
      "title": "Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER2 Gene Mutation",
        "HER-2 Gene Amplification",
        "HER2 Positive Gastric Cancer",
        "Salivary Gland Cancer",
        "Salivary Gland Tumor",
        "Salivary Gland Carcinoma",
        "Salivary Gland Neoplasms",
        "Lung Cancer",
        "Colo-rectal Cancer",
        "Rare Diseases",
        "Solid Tumor",
        "Recurrent Gastric Cancer",
        "Recurrent Colon Cancer",
        "Recurrent Breast Cancer",
        "Head and Neck Cancer",
        "Head and Neck Carcinoma",
        "Bladder Cancer",
        "Cervical Cancer",
        "Liver Cancer",
        "Bile Duct Cancer",
        "Urologic Cancer",
        "Pancreatic Cancer",
        "Prostate Cancer",
        "Recurrent Prostate Cancer",
        "Rectal Cancer",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Renal Cell Cancer",
        "Rectal Cancer Stage II",
        "Rectal Cancer Stage I",
        "Rectal Cancer Stage III",
        "Skin Cancer",
        "Mouth Cancer",
        "Lip Cancer Stage I",
        "Tongue Cancer",
        "Breast Neoplasm Malignant Primary",
        "Larynx Cancer",
        "Tonsil Cancer",
        "Palate Cancer",
        "Mucoepidermoid Carcinoma",
        "Primary Peritoneal Carcinoma",
        "Mucinous Adenocarcinoma Gastric",
        "Mucinous Breast Cancer Recurrent",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "A166",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Klus Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2018-07-16",
      "completion_date": "2022-01-12",
      "has_results": false,
      "last_update_posted_date": "2023-08-03",
      "last_synced_at": "2026-11-15T07:05:56.571Z",
      "location_count": 10,
      "location_summary": "Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03602079"
    },
    {
      "nct_id": "NCT06782542",
      "title": "Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "IDH1 Mutation"
      ],
      "interventions": [
        {
          "name": "Olutasidenib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Justin Watts, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 16,
      "start_date": "2026-03-31",
      "completion_date": "2029-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-11-15T07:05:56.571Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06782542"
    },
    {
      "nct_id": "NCT07522073",
      "title": "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "INCB161734",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Investigator's choice of chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 588,
      "start_date": "2026-04-09",
      "completion_date": "2029-03-19",
      "has_results": false,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-15T07:05:56.571Z",
      "location_count": 69,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 55 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07522073"
    },
    {
      "nct_id": "NCT02954523",
      "title": "Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "EGFR Gene Mutation",
        "Nonsmall Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Osimertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chul Kim",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2016-10",
      "completion_date": "2023-03-03",
      "has_results": true,
      "last_update_posted_date": "2024-07-05",
      "last_synced_at": "2026-11-15T07:05:56.571Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Hackensack, New Jersey",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02954523"
    },
    {
      "nct_id": "NCT05902962",
      "title": "SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Retinal Dystrophy",
        "PRPF31 Mutationassociated Retinal Dystrophy",
        "RP11"
      ],
      "interventions": [
        {
          "name": "VP-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PYC Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2023-04-20",
      "completion_date": "2025-08-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-11-15T07:05:56.571Z",
      "location_count": 6,
      "location_summary": "Jacksonville, Florida • Miami, Florida • Ann Arbor, Michigan + 3 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05902962"
    },
    {
      "nct_id": "NCT07748403",
      "title": "A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Wilson Disease",
        "Wilson's Disease",
        "Wilsons Disease"
      ],
      "interventions": [
        {
          "name": "PM577a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prime Medicine, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2026-09",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-11-15T07:05:56.571Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut • Chicago, Illinois • San Antonio, Texas",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07748403"
    }
  ]
}